BusinessFDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.By Nasdaq OMXFeb 8, 2018, 11:30 PM UTC
BusinessArbutus Consolidates HBV Business Around Warminster, PA SiteBy Nasdaq OMXFeb 8, 2018, 1:32 PM UTC
BusinessVirta Health's Treatment for Sustained Type 2 Diabetes Reversal Provides New Hope for Chronic Disease PatientsBy Nasdaq OMXFeb 7, 2018, 8:00 PM UTC
BusinessMyriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic MutationBy Nasdaq OMXFeb 7, 2018, 12:05 PM UTC
BusinessNewLink Genetics to Participate in Upcoming Investor ConferencesBy Nasdaq OMXFeb 6, 2018, 2:00 PM UTC
BusinessFibrocell to Present at 20th Annual BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 6, 2018, 1:00 PM UTC
BusinessFibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized SclerodermaBy Nasdaq OMXFeb 5, 2018, 1:01 PM UTC
